Investors Slam MannKind After FDA Balks On Afrezza
Shareholders of pharmaceutical company MannKind Corp. have filed a class action accusing the firm of misleading investors about its diabetes drug Afrezza, which failed to win approval from federal regulators in...To view the full article, register now.
Already a subscriber? Click here to view full article